ClinicalTrials.gg
CompletedNCT03277105Updated Apr 29, 2025Results posted

A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma

A Phase 3 interventional study of Dara SC and Dara IV in Multiple Myeloma, sponsored by Janssen Research & Development, LLC. Completed at 146 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-29.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
522
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 132 studies testing daratumumab in Multiple Myeloma — 21 open to participants now, 63 under way, 10 of them phase 3. daratumumab · Multiple Myeloma.

Enrollment
10th of 132
522 · median 50
Started
2017
with 11 others
Phase 3
24 of 132
4 open now
Registered
31st of 132
by date
Lead sponsor
17 of 132
Janssen Research & Development, LLC

Among the 132 studies testing daratumumab in Multiple Myeloma, this one is the 10th largest by enrollment, is one of 12 that started in 2017, is one of 24 in phase 3, and was the 31st registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

21 of the 132 studies testing daratumumab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About daratumumab

daratumumab: first FDA approval 2015 (DARZALEX), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies testing daratumumab in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of this study is to show that subcutaneous (SC) administration of daratumumab co-formulated with recombinant human hyaluronidase PH20 (Dara SC) is non-inferior to intravenous (IV) administration of daratumumab (Dara IV) in terms of the overall response rate (ORR) and maximum trough concentration (Ctrough).

Read the detailed description

The study population will consist of adults diagnosed with multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or whose disease is refractory to both a PI and an IMiD. The study consists of 3 phases: a screening phase (up to 28 days), a treatment phase, and a follow-up phase. Efficacy, pharmacokinetics, immunogenicity, biomarkers and safety will be assessed at scheduled time. Follow-up will continue until the end of the data collection period, approximately 24 months after the last participant was randomized or when the median overall survival for both arms has been reached, whichever occurs first. The primary hypotheses is that the ORR and maximum Ctrough for Dara SC 1800 milligram (mg) are not inferior to the ORR and maximum Ctrough, respectively, for Dara IV 16 mg per kilogram (mg/kg) in participants with multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or whose disease is refractory to both a PI and an IMiD.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Evidence of a response (Partial response [PR] or better based on investigator's determination of response by international myeloma working group [IMWG] criteria) to at least 1 prior treatment regimen
  • Received at least 3 including a proteasome inhibitor (PI) (greater than or equal to [>=] 2 cycles or 2 months of treatment) and an immunomodulatory drug (IMiD) (>=2 cycles or 2 months of treatment) in any order during the course of treatment (except for participants who discontinued either of these treatments due to a severe allergic reaction within the first 2 cycles/months). A single line of therapy may consist of 1 or more agents, and may include induction, hematopoietic stem cell transplantation, and maintenance therapy. Radiotherapy, bisphosphonate, or a single short course of (no more than the equivalent of dexamethasone 40 milligram/day [mg/day] for 4 days) would not be considered prior lines of therapy
  • Documented multiple myeloma as defined by the criteria below:

    1. Multiple myeloma diagnosis according to the IMWG diagnostic criteria
    2. at Screening as defined by any of the following:

      1. Serum M-protein level >=1.0 gram per deciliter (g/dL) or urine M-protein level >=200 mg/24 hours; or
      2. Light chain multiple myeloma without measurable disease in the serum or the urine: Serum immunoglobulin free light chain (FLC) >=10 mg/dL and abnormal serum immunoglobulin kappa lambda FLC ratio
  • (ECOG) performance status score of 0, 1, or 2
  • Meet the clinical laboratory criteria as specified in the protocol
  • Women of must have a negative urine or serum pregnancy test at screening within 14 days prior to randomization

Exclusion criteria

Exclusion Criteria:

  • Received daratumumab or other anti-CD38 therapies previously
  • Received anti-myeloma treatment within 2 weeks or 5 pharmacokinetic half-lives of the treatment, whichever is longer, before the date of randomization. The only exception is emergency use of a short course of (equivalent of dexamethasone 40 mg/day for a maximum of 4 days) before treatment
  • Received stem cell transplant within 12 weeks before the date of randomization, or the participant has previously received allogeneic stem cell transplant (regardless of timing)
  • Plans to undergo a stem cell transplant prior to progression of disease on this study (these participants should not be enrolled to reduce disease burden prior to transplant)
  • History of (other than multiple myeloma) unless all treatment of that malignancy was completed at least 2 years before consent and the patient has no evidence of disease. Further exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or breast, or other non-invasive lesion, that in the opinion of the investigator, with concurrence with the sponsor's medical monitor, is considered cured with minimal risk of recurrence within 3 years
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
522 participants (actual)

Study arms

  • Experimental
    Dara SC

    Participants will receive a fixed dose of daratumumab as 1800 milligram (mg) subcutaneously (Dara SC) co-formulated with recombinant human hyaluronidase (rHuPH20) 2000 Unit per milliliter (U/mL), once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study. The duration for each cycle is 4 weeks.

    Drug: Dara SC

  • Active comparator
    Dara IV

    Participants will receive daratumumab for intravenous infusion (Dara IV) 16 mg/kg once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks on Day 1 in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study. The duration for each cycle is 4 weeks. For Participants still receiving treatment with Dara-IV at the time of Protocol Amendment 4 the duration of infusion may be shortened to a 90-minute infusion or participants will have the option to switch to Dara 1800 mg subcutaneous (SC) on Day 1 of any cycle, at the discretion of the investigator.

    Drug: Dara SC · Drug: Dara IV

Interventions

  • DrugDara SC

    Participants will receive a fixed dose of Dara SC as 1800 mg daratumumab with rHuPH20 2000 U/mL, once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study.

  • Participants will receive Dara IV 16 mg/kg once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study.

    Also known as: JNJ-54767414

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    ORR was defined as the percentage of participants who achieved partial response (PR) or better according to International Myeloma Working Group (IMWG) criteria, during or after study treatment. IMWG criteria for PR: greater than or equal to (\>=) 50 percent (%) reduction of serum M-protein and reduction in 24-hour urinary M-protein by \>=90% or to less than (\<) 200 milligrams (mg)/24 hours, If the serum and urine M-proteins are not measurable, a decrease of \>=50% in the difference between involved and uninvolved free light chain (FLC) levels were required in place of the M-protein criteria, If serum and urine M-protein are not measurable, and serum free light assay was also not measurable, \>=50% reduction in bone marrow plasma cells (PCs) was required in place of M-protein, provided baseline bone marrow plasma cell percentage was \>=30%. In addition to the above criteria, if present at baseline, a \>=50% reduction in the size of soft tissue plasmacytomas was also required.

    Time frame: Up to 1 year 8 months

  2. Maximum Trough Concentration (Ctrough) of Daratumumab

    Maximum Ctrough was defined as the serum predose concentration of daratumumab on Cycle 3 Day 1.

    Time frame: Predose on Cycle 3 Day 1 (each cycle of 28 days)

Secondary outcomes

  1. Percentage of Participants With Treatment-emergent Infusion-related Reactions (IRR)

    Percentage of participants with treatment-emergent infusion-related reactions were reported.

    Time frame: Up to 3 years

  2. Progression Free Survival (PFS)

    PFS was defined as time from date of randomization to either progression of disease (PD), death due to any cause, whichever occurs first. IMWG criteria for PD: Increase of 25% from lowest response value in any one of the following: Serum M component (absolute increase must be \>=0.5 gram per deciliter (g/dL), Urine M-component (absolute increase must be \>=200 mg/24 hours), Participants without measurable serum and urine Mprotein levels: difference between involved and uninvolved free light chain (FLC) levels (absolute increase must be \>10 milligrams per deciliter (mg/dL), participants without measurable serum and urine M-protein levels and without measurable disease by FLC levels, bone marrow PC% (absolute percentage must be \>=10%), definite development of new bone lesions or soft tissue plasmacytomas or increase in size of bone lesions or tissue plasmacytomas and development of hypercalcemia (serum calcium \>11.5 mg/dL) that can be attributed solely to PC proliferative disorder.

    Time frame: Up to 3 years

  3. Percentage of Participants With Very Good Partial Response (VGPR) or Better

    VGPR or better was defined as the percentage of participants who achieved VGPR or better (VGPR, complete response (CR) or stringent complete response \[sCR\]), based on computerized algorithm as per IMWG criteria during or after the study treatment. IMWG criteria for VGPR: Serum and urine M-component detectable by immunofixation but not on electrophoresis, or \>=90 percent (%) reduction in serum M-protein plus urine M-protein \<100 milligrams (mg)/24 hours, CR: Negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas and \<5% plasma cells (PCs) in bone marrow. sCR: CR plus normal FLC ratio, and absence of clonal PCs by immunohistochemistry (IHC), immunofluorescencea or 2- to 4 color flow cytometry.

    Time frame: Up to 3 years

  4. Percentage of Participants With Complete Response (Including sCR) or Better

    CR or better was defined as percentage of participants with a CR or better (CR or stringent complete response \[sCR\]) based on computerized algorithm as per IMWG criteria. IMWG criteria for CR- negative immunofixation on the serum and urine, and disappearance of any soft tissue plasmacytomas, and \<5% PCs in bone marrow. sCR: CR plus normal FLC ratio, and absence of clonal PCs by IHC, immunofluorescencea or 2- to 4 color flow cytometry.

    Time frame: Up to 3 years

  5. Time to Next Therapy

    Time to next therapy was defined as the time from randomization to the start of the first subsequent anti-cancer therapy.

    Time frame: Up to 3 years

  6. Overall Survival (OS)

    OS was defined as the time from the date of randomization to the date of the participant's death due to any cause.

    Time frame: Up to 3 years

  7. Patient-Reported Satisfaction With Therapy as Assessed With Cancer Therapy Satisfaction Questionnaire (CTSQ)

    Modified-CTSQ contain 9 items (2 items for Thoughts about Cancer Therapy and 7 items in a defined domain of Satisfaction with Therapy) specific to satisfaction with therapy and for comparison of SC and IV administration. Satisfaction with therapy was calculated based on 7-items using 5-point verbal rating scale, where 1= never and 5= always. Scores were averaged and transformed to a 0-100 scale; higher scores represent better health. At least 5 of the 7 items within the Satisfaction with Therapy domain had to be completed to calculate a domain score. No domain score was calculated for Thoughts about Cancer Therapy.

    Time frame: Cycle 1 (Days 8,15 and 22), Cycle 2 (Days 1,8,15 and 22), Cycle 3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21 and 22 (Day 1)

  8. Duration of Response

    Duration of response was defined as the duration from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease according to the IMWG criteria. PD was defined as an increase of 25 % from the lowest response value in one of the following: serum and urine M-component (absolute increase must be \>= 0.5 g/dL and \>=200 mg/24 hours respectively); Only in participants without measurable serum and urine M-protein levels the difference between involved and uninvolved FLC levels (absolute increase must be \> 10 mg/dL); Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to PC proliferative disorder.

    Time frame: Up to 3 years

  9. Time to Partial Response (PR) or Better

    Time to PR or better was defined as the time from randomization until onset of first response of PR or better.

    Time frame: Up to 3 years

  10. Time to Very Good Partial Response (VGPR) or Better

    Time to VGPR or better was defined as the time from randomization until onset of first VGPR or better.

    Time frame: Up to 3 years

  11. Time to Complete Response (CR) or Better

    Time to CR or better was defined as the time from randomization until onset of first CR or better.

    Time frame: Up to 3 years

07

Results

Posted Jul 27, 2020

Participant flow

Participant flow — Overall Study
MilestoneDaratumumab IVDaratumumab SC
Started259263
Treated (safety analysis set)258260
Completed00
Not completed259263
Withdrew: Death129124
Withdrew: Lost to follow-up24
Withdrew: Withdrawal by subject1010
Withdrew: Other118125

Outcome measures

PrimaryOverall Response Rate (ORR)

ORR was defined as the percentage of participants who achieved partial response (PR) or better according to International Myeloma Working Group (IMWG) criteria, during or after study treatment. IMWG criteria for PR: greater than or equal to (\>=) 50 percent (%) reduction of serum M-protein and reduction in 24-hour urinary M-protein by \>=90% or to less than (\<) 200 milligrams (mg)/24 hours, If the serum and urine M-proteins are not measurable, a decrease of \>=50% in the difference between involved and uninvolved free light chain (FLC) levels were required in place of the M-protein criteria, If serum and urine M-protein are not measurable, and serum free light assay was also not measurable, \>=50% reduction in bone marrow plasma cells (PCs) was required in place of M-protein, provided baseline bone marrow plasma cell percentage was \>=30%. In addition to the above criteria, if present at baseline, a \>=50% reduction in the size of soft tissue plasmacytomas was also required.

Time frame:
Up to 1 year 8 months
Reported as:
Number · Percentage of participants
Overall Response Rate (ORR)
Percentage of participantsDaratumumab IVDaratumumab SC
Overall Response Rate (ORR)39.4 (33.4 to 45.6)43.3 (37.3 to 49.6)
PrimaryMaximum Trough Concentration (Ctrough) of Daratumumab

Maximum Ctrough was defined as the serum predose concentration of daratumumab on Cycle 3 Day 1.

Time frame:
Predose on Cycle 3 Day 1 (each cycle of 28 days)
Reported as:
Mean · micrograms per milliliter (mcg/mL)
Maximum Trough Concentration (Ctrough) of Daratumumab
micrograms per milliliter (mcg/mL)Daratumumab IVDaratumumab SC
Maximum Trough Concentration (Ctrough) of Daratumumab525 ± 227611 ± 318
SecondaryPercentage of Participants With Treatment-emergent Infusion-related Reactions (IRR)

Percentage of participants with treatment-emergent infusion-related reactions were reported.

Time frame:
Up to 3 years
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment-emergent Infusion-related Reactions (IRR)
Percentage of participantsDaratumumab IVDaratumumab SC
Percentage of Participants With Treatment-emergent Infusion-related Reactions (IRR)34.5 (28.7 to 40.6)12.7 (8.9 to 17.4)
SecondaryProgression Free Survival (PFS)

PFS was defined as time from date of randomization to either progression of disease (PD), death due to any cause, whichever occurs first. IMWG criteria for PD: Increase of 25% from lowest response value in any one of the following: Serum M component (absolute increase must be \>=0.5 gram per deciliter (g/dL), Urine M-component (absolute increase must be \>=200 mg/24 hours), Participants without measurable serum and urine Mprotein levels: difference between involved and uninvolved free light chain (FLC) levels (absolute increase must be \>10 milligrams per deciliter (mg/dL), participants without measurable serum and urine M-protein levels and without measurable disease by FLC levels, bone marrow PC% (absolute percentage must be \>=10%), definite development of new bone lesions or soft tissue plasmacytomas or increase in size of bone lesions or tissue plasmacytomas and development of hypercalcemia (serum calcium \>11.5 mg/dL) that can be attributed solely to PC proliferative disorder.

Time frame:
Up to 3 years
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsDaratumumab IVDaratumumab SC
Progression Free Survival (PFS)6.08 (4.73 to 7.43)5.62 (4.70 to 7.49)
SecondaryPercentage of Participants With Very Good Partial Response (VGPR) or Better

VGPR or better was defined as the percentage of participants who achieved VGPR or better (VGPR, complete response (CR) or stringent complete response \[sCR\]), based on computerized algorithm as per IMWG criteria during or after the study treatment. IMWG criteria for VGPR: Serum and urine M-component detectable by immunofixation but not on electrophoresis, or \>=90 percent (%) reduction in serum M-protein plus urine M-protein \<100 milligrams (mg)/24 hours, CR: Negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas and \<5% plasma cells (PCs) in bone marrow. sCR: CR plus normal FLC ratio, and absence of clonal PCs by immunohistochemistry (IHC), immunofluorescencea or 2- to 4 color flow cytometry.

Time frame:
Up to 3 years
Reported as:
Number · Percentage of participants
Percentage of Participants With Very Good Partial Response (VGPR) or Better
Percentage of participantsDaratumumab IVDaratumumab SC
Percentage of Participants With Very Good Partial Response (VGPR) or Better21.6 (16.8 to 27.1)23.6 (18.6 to 29.2)
SecondaryPercentage of Participants With Complete Response (Including sCR) or Better

CR or better was defined as percentage of participants with a CR or better (CR or stringent complete response \[sCR\]) based on computerized algorithm as per IMWG criteria. IMWG criteria for CR- negative immunofixation on the serum and urine, and disappearance of any soft tissue plasmacytomas, and \<5% PCs in bone marrow. sCR: CR plus normal FLC ratio, and absence of clonal PCs by IHC, immunofluorescencea or 2- to 4 color flow cytometry.

Time frame:
Up to 3 years
Reported as:
Number · Percentage of participants
Percentage of Participants With Complete Response (Including sCR) or Better
Percentage of participantsDaratumumab IVDaratumumab SC
Percentage of Participants With Complete Response (Including sCR) or Better5.4 (3.0 to 8.9)4.6 (2.4 to 7.8)
SecondaryTime to Next Therapy

Time to next therapy was defined as the time from randomization to the start of the first subsequent anti-cancer therapy.

Time frame:
Up to 3 years
Reported as:
Median · Months
Time to Next Therapy
MonthsDaratumumab IVDaratumumab SC
Time to Next Therapy9.43 (8.15 to 10.71)8.80 (7.59 to 10.91)
SecondaryOverall Survival (OS)

OS was defined as the time from the date of randomization to the date of the participant's death due to any cause.

Time frame:
Up to 3 years
Reported as:
Median · Months
Overall Survival (OS)
MonthsDaratumumab IVDaratumumab SC
Overall Survival (OS)25.56 (22.05 to NA)28.19 (22.77 to NA)
SecondaryPatient-Reported Satisfaction With Therapy as Assessed With Cancer Therapy Satisfaction Questionnaire (CTSQ)

Modified-CTSQ contain 9 items (2 items for Thoughts about Cancer Therapy and 7 items in a defined domain of Satisfaction with Therapy) specific to satisfaction with therapy and for comparison of SC and IV administration. Satisfaction with therapy was calculated based on 7-items using 5-point verbal rating scale, where 1= never and 5= always. Scores were averaged and transformed to a 0-100 scale; higher scores represent better health. At least 5 of the 7 items within the Satisfaction with Therapy domain had to be completed to calculate a domain score. No domain score was calculated for Thoughts about Cancer Therapy.

Time frame:
Cycle 1 (Days 8,15 and 22), Cycle 2 (Days 1,8,15 and 22), Cycle 3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21 and 22 (Day 1)
Reported as:
Mean · Units on a scale
Patient-Reported Satisfaction With Therapy as Assessed With Cancer Therapy Satisfaction Questionnaire (CTSQ)
Units on a scaleDaratumumab IVDaratumumab SC
Cycle 1 Day 870.5 ± 15.9876.9 ± 14.64
Cycle 1 Day 1572.1 ± 16.7278.8 ± 14.95
Cycle 1 Day 2272.8 ± 16.2078.7 ± 15.75
Cycle 2 Day 174.2 ± 16.4479.7 ± 16.58
Cycle 2 Day 874.8 ± 15.5780.1 ± 17.24
Cycle 2 Day 1574.3 ± 16.9480.0 ± 17.37
Cycle 2 Day 2275.2 ± 16.4779.3 ± 18.65
Cycle 3 Day 176.0 ± 17.3980.4 ± 17.78
Cycle 4 Day 176.6 ± 17.2279.5 ± 19.88
Cycle 5 Day 177.1 ± 17.1179.6 ± 18.95
Cycle 6 Day 176.1 ± 17.7981.9 ± 18.34
Cycle 7 Day 178.6 ± 16.0185.0 ± 16.87
Cycle 8 Day 179.2 ± 15.5485.0 ± 15.18
Cycle 9 Day 179.8 ± 15.2785.2 ± 15.03
Cycle 10 Day 179.4 ± 14.7385.8 ± 13.31
Cycle 11 Day 179.1 ± 15.5584.8 ± 13.50
Cycle 12 Day 180.3 ± 15.8885.4 ± 14.70
Cycle 13 Day 179.6 ± 16.5784.4 ± 15.09
Cycle 14 Day 180.6 ± 14.6283.5 ± 15.54
Cycle 15 Day 180.2 ± 15.2286.2 ± 13.51
Cycle 16 Day 179.4 ± 14.8488.5 ± 13.10
Cycle 17 Day 179.0 ± 14.3490.9 ± 11.26
Cycle 18 Day 184.8 ± 14.1391.4 ± 11.57
Cycle 19 Day 192.9 ± 10.1089.3 ± 13.36
Cycle 20 Day 1—86.6 ± 18.53
Cycle 21 Day 1—84.5 ± 20.93
Cycle 22 Day 1—96.4
SecondaryDuration of Response

Duration of response was defined as the duration from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease according to the IMWG criteria. PD was defined as an increase of 25 % from the lowest response value in one of the following: serum and urine M-component (absolute increase must be \>= 0.5 g/dL and \>=200 mg/24 hours respectively); Only in participants without measurable serum and urine M-protein levels the difference between involved and uninvolved FLC levels (absolute increase must be \> 10 mg/dL); Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to PC proliferative disorder.

Time frame:
Up to 3 years
Reported as:
Median · Months
Duration of Response
MonthsDaratumumab IVDaratumumab SC
Duration of Response10.64 (9.23 to 15.64)10.15 (9.23 to 13.77)
SecondaryTime to Partial Response (PR) or Better

Time to PR or better was defined as the time from randomization until onset of first response of PR or better.

Time frame:
Up to 3 years
Reported as:
Median · Months
Time to Partial Response (PR) or Better
MonthsDaratumumab IVDaratumumab SC
Time to Partial Response (PR) or Better1.02 (0.9 to 24.8)1.02 (0.9 to 9.4)
SecondaryTime to Very Good Partial Response (VGPR) or Better

Time to VGPR or better was defined as the time from randomization until onset of first VGPR or better.

Time frame:
Up to 3 years
Reported as:
Median · Months
Time to Very Good Partial Response (VGPR) or Better
MonthsDaratumumab IVDaratumumab SC
Time to Very Good Partial Response (VGPR) or Better1.92 (0.9 to 22.8)1.95 (1.0 to 19.4)
SecondaryTime to Complete Response (CR) or Better

Time to CR or better was defined as the time from randomization until onset of first CR or better.

Time frame:
Up to 3 years
Reported as:
Median · months
Time to Complete Response (CR) or Better
monthsDaratumumab IVDaratumumab SC
Time to Complete Response (CR) or Better7.23 (1.1 to 14.9)9.26 (1.2 to 23.1)

Adverse events

Collected over Up to 3 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Daratumumab IV130/258 (50.4%)89/258 (34.5%)216/258 (83.7%)
Daratumumab SC126/260 (48.5%)83/260 (31.9%)217/260 (83.5%)
Most frequent serious events
Showing 10 of 134
Most frequent serious events
EventDaratumumab IVDaratumumab SC
PneumoniaInfections and infestations13/25812/260
General Physical Health DeteriorationGeneral disorders6/2584/260
PyrexiaGeneral disorders6/2584/260
AnaemiaBlood and lymphatic system disorders4/2586/260
Lung InfectionInfections and infestations2/2585/260
Bone PainMusculoskeletal and connective tissue disorders3/2585/260
ThrombocytopeniaBlood and lymphatic system disorders4/2583/260
Lower Respiratory Tract InfectionInfections and infestations4/2583/260
SepsisInfections and infestations4/2584/260
Septic ShockInfections and infestations4/2583/260
Most frequent other events
Showing 10 of 31
Most frequent other events
EventDaratumumab IVDaratumumab SC
AnaemiaBlood and lymphatic system disorders64/25871/260
NeutropeniaBlood and lymphatic system disorders34/25852/260
ThrombocytopeniaBlood and lymphatic system disorders50/25849/260
Upper Respiratory Tract InfectionInfections and infestations30/25844/260
DiarrhoeaGastrointestinal disorders32/25841/260
Back PainMusculoskeletal and connective tissue disorders36/25831/260
CoughRespiratory, thoracic and mediastinal disorders36/25825/260
PyrexiaGeneral disorders34/25836/260
FatigueGeneral disorders26/25833/260
ArthralgiaMusculoskeletal and connective tissue disorders18/25833/260

Baseline characteristics

Age, Continuous
Age, Continuous(years)Daratumumab IVDaratumumab SCTotal
Mean66.8 ± 10.1665.3 ± 9.1166.1 ± 9.66
Sex: Female, Male
Sex: Female, Male(Participants)Daratumumab IVDaratumumab SCTotal
Female110127237
Male149136285
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Daratumumab IVDaratumumab SCTotal
Hispanic or Latino91423
Not Hispanic or Latino227225452
Unknown or Not Reported232447
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Daratumumab IVDaratumumab SCTotal
American Indian or Alaska Native011
Asian403272
Native Hawaiian or Other Pacific Islander101
Black or African American5914
White201207408
More than one race000
Unknown or Not Reported121426
Region of Enrollment
Region of Enrollment(Participants)Daratumumab IVDaratumumab SCTotal
AUSTRALIA151328
BRAZIL101525
CANADA162036
CZECH REPUBLIC201636
FRANCE61016
GREECE167
ISRAEL5813
ITALY101626
JAPAN241842
POLAND392665
RUSSIAN FEDERATION282755
SOUTH KOREA7411
SPAIN141226
SWEDEN181836
TAIWAN6814
UKRAINE222547
UNITED KINGDOM161733
UNITED STATES246
Stage of Disease (ISS)
Stage of Disease (ISS)(Participants)Daratumumab IVDaratumumab SCTotal
Stage I9482176
Stage II89101190
Stage III7679155
Data missing or Unknown011
Number of prior lines
Number of prior lines(Participants)Daratumumab IVDaratumumab SCTotal
Less than or equal to (<=) 4 Lines175174349
Greater than (>) 4 Lines8489173
Refractory status
Refractory status(Participants)Daratumumab IVDaratumumab SCTotal
Both protease inhibitor (PI) and immunomodulatory drug (IMiD)133125258
IMiD only8167148
None264167
PI only193049

1 further baseline measures are reported on the registry.

08

Study locations

146 sites
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215-5418, United States
  • Levine Cancer Institute
    Charlotte, North Carolina 28204, United States
  • Royal Prince Alfred Hospital
    Camperdown, 2050, Australia
  • St Vincents Hospital Melbourne
    Fitzroy, 3065, Australia
  • Alfred Health
    Melbourne, 3004, Australia
  • Fiona Stanley Hospital
    Murdoch, 6150, Australia
  • Sir Charles Gairdner Hospital
    Nedlands, 6009, Australia
  • Calvary Mater Newcastle Hospital
    Waratah, 2298, Australia
  • The Queen Elizabeth Hospital
    Woodville South, 5011, Australia
  • Princess Alexandra Hospital
    Woolloongabba, 4102, Australia
  • Fundacao Pio XII
    Barretos, 14784-400, Brazil
  • Centro de Pesquisa e Ensino em Oncologia de Santa Catarina CEPEN
    Florianopolis, 88034-000, Brazil
  • Fundacao Doutor Amaral Carvalho
    Jau, 17210 080, Brazil
  • Instituto Joinvilense de Hematologia e Oncologia Ltda Centro de Hematologia e Oncologia
    Joinville, 89201-260, Brazil
  • Associacao Hospitalar Beneficente Sao Vicente de Paulo - Hospital Sao Vicente de Paulo
    Passo Fundo, 99010-090, Brazil
  • Hospital das Clinicas de Porto Alegre
    Porto Alegre, 90035-903, Brazil
  • Instituto de Educacao, Pesquisa e Gestao em Saude
    Rio de Janeiro, 22775-001, Brazil
  • CEHON
    Salvador, 45995-000, Brazil
  • Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto Hospital de Base
    Sao Jose do Rio Preto, 15090-000, Brazil
  • Clinica Sao Germano
    São Paulo, 01455 010, Brazil
  • Hospital Das Clinicas Da Faculdade De Medicina Da USP
    São Paulo, 05403-010, Brazil
  • Tom Baker Cancer Centre
    Calgary, Alberta T2N 4N2, Canada
  • Cross Cancer Institute
    Edmonton, Alberta T6G 1Z2, Canada
  • The Gordon & Leslie Diamond Health Care Center
    Vancouver, British Columbia V5Z 1M9, Canada
  • QEII Health Sciences Centre
    Halifax, Nova Scotia B3H 1V7, Canada
  • Victoria Hospital
    London, Ontario N6A 5W9, Canada
  • Princess Margaret Hospital
    Toronto, Ontario M5G 1X6, Canada
  • CHU de Quebec L Hotel Dieu de Quebec
    Québec, Quebec G1R 2J6, Canada
  • Fakultni nemocnice Brno
    Brno, 625 00, Czechia
  • Fakultni nemocnice Hradec Kralove
    Hradec Kralove, 500 05, Czechia
  • Fakultni nemocnice Olomouc
    Olomouc, 779 00, Czechia
  • Fakultni Nemocnice Ostrava
    Ostrava, 70852, Czechia
  • Fakultni nemocnice Plzen, Hemato-onkologicke oddeleni
    Plzen, 323 00, Czechia
  • Fakultni nemocnice Kralovske Vinohrady
    Praha 10, 100 34, Czechia
  • Vseobecna fakultni nemocnice v Praze - I. interni klinika - klinika hematologie
    Praha 2, 128 08, Czechia
  • CHU Caen - Côte de Nacre
    Caen, 14033, France
  • Hopital Claude Huriez
    Lille Cedex, 59000, France
  • CHU de Nantes hotel Dieu
    Nantes Cedex 1, 44093, France
  • CHU de Boreaux
    Pessac, 33604, France
  • Centre hospitalier Lyon-Sud
    Pierre-Bénite, 69495, France
  • CHU Poitiers - Hopital la Miletrie
    Poitiers, 86021, France
  • CHU Nancy Brabois
    Vandoeuvre Les Nancy, 54511, France
  • Alexandra General Hospital of Athens
    Athens Attica, 115 28, Greece
  • Hillel Yaffe Medical Center - Oncology
    Hadera, 38100, Israel
  • Rambam Med.Center - Hematology Institute
    Haifa, 31096, Israel
  • Carmel Medical Center
    Haifa, 3436212, Israel
  • Hadassah Medical Center
    Jerusalem, 91120, Israel
  • Rabin Medical Center Beilinson Campus
    Petah Tikva, 49100, Israel
  • Sheba Medical Center Tel Hashomer
    Ramat Gan, 52621, Israel
  • Tel Aviv Sourasky Medical Center
    Tel Aviv, 64239, Israel
  • Policlinico Sant'Orsola Malpighi
    Bologna, 40138, Italy
  • Fondazione IRCCS Istituto Nazionale dei Tumori
    Milano, 20133, Italy
  • Ospedale Villa Sofia-Cervello
    Palermo, 90146, Italy
  • Fondazione IRCCS Policlinico San Matteo
    Pavia, 27100, Italy
  • Azienda USL di Piacenza
    Piacenza, 29121, Italy
  • Università di Roma La Sapienza
    Roma, 00161, Italy
  • Policlinico Universitario Agostino Gemelli
    Roma, 00168, Italy
  • A.O.U. Città della Salute e della Scienza
    Torino, 10126, Italy
  • Fukuoka University Hospital
    Fukuoka, 814-0180, Japan
  • Chugoku Central Hospital
    Fukuyama, 720-0001, Japan
  • Ogaki Municipal Hospital
    Gifu, 503-8502, Japan
  • Gunma University Hospital
    Gunma, 371-0034, Japan
  • Iwate Medical University Hospital
    Iwate, 020-8505, Japan
  • Kobe City Medical Center General Hospital
    Kobe City, 650 0047, Japan
  • University Hospital Kyoto Prefectural University of Medicine
    Kyoto, 602-8566, Japan
  • Matsuyama Red Cross Hospital
    Matsuyama, 790-8524, Japan
  • Japanese Red Cross Nagoya Daini Hospital
    Nagoya, 466-8650, Japan
  • Nagoya City University Hospital
    Nagoya, 467 8602, Japan
  • Niigata Cancer Center Hospital
    Niigata, 951-8566, Japan
  • National Hospital Organization Okayama Medical Center
    Okayama, 701-1192, Japan
  • Osaka University Hospital
    Osaka, 565-0871, Japan
  • National Hospital Organization Sendai Medical Center
    Sendai-City, 983-8520, Japan
  • National Hospital Organization Shibukawa Medical Center
    Shibukawa, 377-0280, Japan
  • Japanese Red Cross Medical Center
    Shibuya, 150-8935, Japan
  • Pusan National University Hospital
    Busan, 49241, Korea, Republic of
  • National Cancer Center
    Goyang-Si, 10408, Korea, Republic of
  • Gachon University Gil Medical Center
    Incheon, 21565, Korea, Republic of
  • Severance Hospital
    Seoul, 03722, Korea, Republic of
  • Asan Medical Center
    Seoul, 05505, Korea, Republic of
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
  • The Catholic University of Korea Seoul St Marys Hospital
    Seoul, 06591, Korea, Republic of
  • Ulsan University Hospital
    Ulsan, 44033, Korea, Republic of
  • Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny im Ks B Markiewicza
    Brzozow, 36-200, Poland
  • Szpital Uniwersytecki nr 2 im. Jana Biziela w Bydgoszczy
    Bydgoszcz, 85-168, Poland
  • Samodzielny Publiczny Zaklad Opieki Zdrowotnej Zespol Szpitali Miejskich
    Chorzow, 41-500, Poland
  • Szpitale Pomorskie Sp z o o
    Gdynia, 81 519, Poland
  • Szpital Uniwersytecki w Krakowie
    Krakow, 31 501, Poland
  • Wojewodzki Szpital Specjalistyczny w Legnicy
    Legnica, 59-220, Poland
  • Samodzielny Publiczny Szpital Kliniczny nr 1 w Lublinie
    Lublin, 20-081, Poland
  • Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im Karola Marcinkowskiego
    Poznan, 60 569, Poland
  • Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
    Warszawa, 02-781, Poland
  • Emergency Hospital of Dzerzhinsk
    Dzerzhinsk, 606019, Russian Federation
  • Ekaterinburg City Clinical Hospital # 7
    Ekaterinburg, 620137, Russian Federation
  • S.P. Botkin Moscow City Clinical Hospital
    Moscow, 125284, Russian Federation
  • City Clinical Hospital # 40
    Moscow, 129301, Russian Federation
  • Nizhniy Novgorod Region Clinical Hospital
    Nizny Novgorod, 603126, Russian Federation
  • Penza Regional Oncology Dispensary
    Penza, 440071, Russian Federation
  • Ryazan Regional Clinical Hospital
    Ryazan, 390039, Russian Federation
  • Saint Petersburg City Hospital #15
    Saint-Petersburg, 123182, Russian Federation
  • Samara Region Clinical Hospital
    Samara, 443095, Russian Federation

Showing the first 100 of 146 sites across 18 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Usmani SZ, Nahi H, Legiec W, Grosicki S, Vorobyev V, Spicka I, Hungria V, Korenkova S, Bahlis NJ, Flogegard M, Blade J, Moreau P, Kaiser M, Iida S, Laubach J, Magen H, Cavo M, Hulin C, White D, De Stefano V, Lantz K, O'Rourke L, Heuck C, Delioukina M, Qin X, Nnane I, Qi M, Mateos MV. Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma. Haematologica. 2022 Oct 1;107(10):2408-2417. doi: 10.3324/haematol.2021.279459. PubMed 35354247 ↗
  • Iida S, Ishikawa T, Min CK, Kim K, Yeh SP, Usmani SZ, Mateos MV, Nahi H, Heuck C, Qin X, Parasrampuria DA, Gries KS, Qi M, Bahlis N, Ito S. Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study. Ann Hematol. 2021 Apr;100(4):1065-1077. doi: 10.1007/s00277-021-04405-2. Epub 2021 Feb 18. PubMed 33599794 ↗
  • Usmani SZ, Mateos MV, Hungria V, Iida S, Bahlis NJ, Nahi H, Magen H, Cavo M, Hulin C, White D, De Stefano V, Fastenau J, Slavcev M, Heuck C, Qin X, Pei H, Masterson T, Lantz K, Gries KS. Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results. J Cancer Res Clin Oncol. 2021 Feb;147(2):619-631. doi: 10.1007/s00432-020-03365-w. Epub 2020 Aug 27. PubMed 32852632 ↗
  • Mateos MV, Nahi H, Legiec W, Grosicki S, Vorobyev V, Spicka I, Hungria V, Korenkova S, Bahlis N, Flogegard M, Blade J, Moreau P, Kaiser M, Iida S, Laubach J, Magen H, Cavo M, Hulin C, White D, De Stefano V, Clemens PL, Masterson T, Lantz K, O'Rourke L, Heuck C, Qin X, Parasrampuria DA, Yuan Z, Xu S, Qi M, Usmani SZ. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematol. 2020 May;7(5):e370-e380. doi: 10.1016/S2352-3026(20)30070-3. Epub 2020 Mar 23. PubMed 32213342 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Jun 2019, 20 months.

Results were first posted in Jul 2020, 1 year 1 month after primary completion.

Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 20 months is below that.

Counting every sponsor, half of 178 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2017
First posted
Sep 8, 2017
StartActual
Oct 27, 2017
Primary completionActual
Jun 27, 2019
CompletionActual
Jan 12, 2024
Results first posted
Jul 27, 2020
Last update
Apr 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03277105
Responsible party
Sponsor
First posted
Sep 8, 2017
Start date
Oct 27, 2017
Primary completion
Jun 27, 2019
Completion
Jan 12, 2024
Results posted
Jul 27, 2020
Last update
Apr 29, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Daratumumab

Start the discussion